Dr. Aaron Ring, an assistant professor of immunobiology at Yale, is piloting a new approach to targeting cancerous tumors that has not only drawn the eyes of the biomedical community, but also investors.
His New-Haven based startup Simcha Therapeutics received a $25 million investment, including $1.5 million from Connecticut Innovation’s Bioscience Fund, to underwrite a phase one clinical trial that is set to begin in the first half of 2021.